Your browser doesn't support javascript.
loading
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett, Charles L; Schoen, Martin W; Hoque, Shamia; Witherspoon, Bartlett J; Aboulafia, David M; Hwang, Catherine S; Ray, Paul; Yarnold, Paul R; Chen, Brian K; Schooley, Benjamin; Taylor, Matthew A; Wyatt, Michael D; Hrushesky, William J; Yang, Y Tony.
Afiliación
  • Bennett CL; College of Pharmacy, University of South Carolina, Columbia, SC, USA; WJB Dorn VA Medical Center, Columbia, SC, USA; Department of Comparative Medicine and Evidence Based Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: bennettc@cop.sc.edu.
  • Schoen MW; Saint Louis University School of Medicine, Saint Louis, MO, USA; John Cochran VA Medical Center, Saint Louis, MO, USA.
  • Hoque S; College of Engineering and Computing, University of South Carolina, Columbia, SC, USA; WJB Dorn VA Medical Center, Columbia, SC, USA.
  • Witherspoon BJ; College of Pharmacy, University of South Carolina, Columbia, SC, USA.
  • Aboulafia DM; Virginia Mason Medical Center, Seattle, WA, USA.
  • Hwang CS; Virginia Mason Medical Center, Seattle, WA, USA.
  • Ray P; College of Pharmacy, University of South Carolina, Columbia, SC, USA.
  • Yarnold PR; College of Pharmacy, University of South Carolina, Columbia, SC, USA.
  • Chen BK; The Arnold School of Public Health, University of South Carolina, Columbia, SC, USA; WJB Dorn VA Medical Center, Columbia, SC, USA.
  • Schooley B; College of Engineering and Computing, University of South Carolina, Columbia, SC, USA.
  • Taylor MA; School of Medicine, University of South Carolina, Columbia, SC, USA.
  • Wyatt MD; College of Pharmacy, University of South Carolina, Columbia, SC, USA.
  • Hrushesky WJ; College of Pharmacy, University of South Carolina, Columbia, SC, USA.
  • Yang YT; School of Nursing and Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Lancet Oncol ; 21(12): e575-e588, 2020 12.
Article en En | MEDLINE | ID: mdl-33271114
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: United States Food and Drug Administration / Aprobación de Drogas / Biosimilares Farmacéuticos / Antineoplásicos Inmunológicos / Hematínicos / Neoplasias Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte / Asia / Europa Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: United States Food and Drug Administration / Aprobación de Drogas / Biosimilares Farmacéuticos / Antineoplásicos Inmunológicos / Hematínicos / Neoplasias Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte / Asia / Europa Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido